Brought to you by 
Merck licenses rights to Theravance's cardiovascular projects
25 Jul 2014
Executive Summary
Theravance Inc. (respiratory, infectious, GI, and CNS disease therapies) has granted Merck & Co. Inc. exclusive worldwide discovery, development, and commercialization rights to small-molecule compounds against an undisclosed target for hypertension and heart failure. The initial term of the deal is for one year, and may be extended if both parties agree.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck licenses rights to Theravance's cardiovascular projects
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice